Thank Otezla for Amgen's Q3 Revenue and Earnings Beats
It was beginning to look like a decent year for Amgen (NASDAQ: AMGN) after the company blew past Wall Street estimates with its second-quarter results three months ago. Since then, though, Amgen has come under congressional scrutiny for its drug pricing. The stock has also given up all of its gains and then some.
Amgen announced its third-quarter results after the market closed on Wednesday. Was the big biotech's performance sufficient to excite investors? Here are the highlights from Amgen's Q3 update.
Image Source: Getty Images.
Source Fool.com
